These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

843 related items for PubMed ID: 17634458

  • 1. Certolizumab pegol for the treatment of Crohn's disease.
    Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S, PRECISE 1 Study Investigators.
    N Engl J Med; 2007 Jul 19; 357(3):228-38. PubMed ID: 17634458
    [Abstract] [Full Text] [Related]

  • 2. Maintenance therapy with certolizumab pegol for Crohn's disease.
    Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OØ, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ, PRECISE 2 Study Investigators.
    N Engl J Med; 2007 Jul 19; 357(3):239-50. PubMed ID: 17634459
    [Abstract] [Full Text] [Related]

  • 3. Certolizumab pegol for the management of Crohn's disease in adults.
    Rivkin A.
    Clin Ther; 2009 Jun 19; 31(6):1158-76. PubMed ID: 19695385
    [Abstract] [Full Text] [Related]

  • 4. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.
    Prescrire Int; 2009 Jun 19; 18(101):108-10. PubMed ID: 19637418
    [Abstract] [Full Text] [Related]

  • 5. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data.
    Schreiber S, Colombel JF, Bloomfield R, Nikolaus S, Schölmerich J, Panés J, Sandborn WJ, PRECiSE 2 Study Investigators.
    Am J Gastroenterol; 2010 Jul 19; 105(7):1574-82. PubMed ID: 20234346
    [Abstract] [Full Text] [Related]

  • 6. Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease.
    Smith LS, Nelson M, Dolder CR.
    Ann Pharmacother; 2010 Feb 19; 44(2):333-42. PubMed ID: 20118143
    [Abstract] [Full Text] [Related]

  • 7. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months.
    Lichtenstein GR, Thomsen OØ, Schreiber S, Lawrance IC, Hanauer SB, Bloomfield R, Sandborn WJ, Precise 3 Study Investigators.
    Clin Gastroenterol Hepatol; 2010 Jul 19; 8(7):600-9. PubMed ID: 20117244
    [Abstract] [Full Text] [Related]

  • 8. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease.
    Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, Kamm MA, Boivin M, Bernstein CN, Staun M, Thomsen OØ, Innes A, CDP870 Crohn's Disease Study Group.
    Gastroenterology; 2005 Sep 19; 129(3):807-18. PubMed ID: 16143120
    [Abstract] [Full Text] [Related]

  • 9. Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the PRECiSE 2 study.
    Feagan BG, Reilly MC, Gerlier L, Brabant Y, Brown M, Schreiber S.
    Aliment Pharmacol Ther; 2010 Jun 19; 31(12):1276-85. PubMed ID: 20298497
    [Abstract] [Full Text] [Related]

  • 10. Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial.
    Sandborn WJ, Schreiber S, Feagan BG, Rutgeerts P, Younes ZH, Bloomfield R, Coteur G, Guzman JP, D'Haens GR.
    Clin Gastroenterol Hepatol; 2011 Aug 19; 9(8):670-678.e3. PubMed ID: 21642014
    [Abstract] [Full Text] [Related]

  • 11. Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study.
    Schreiber S, Lawrance IC, Thomsen OØ, Hanauer SB, Bloomfield R, Sandborn WJ.
    Aliment Pharmacol Ther; 2011 Jan 19; 33(2):185-93. PubMed ID: 21083671
    [Abstract] [Full Text] [Related]

  • 12. Meta-analysis: the efficacy and safety of certolizumab pegol in Crohn's disease.
    Shao LM, Chen MY, Cai JT.
    Aliment Pharmacol Ther; 2009 Mar 15; 29(6):605-14. PubMed ID: 19183161
    [Abstract] [Full Text] [Related]

  • 13. Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab.
    Feagan BG, Sandborn WJ, Wolf DC, Coteur G, Purcaru O, Brabant Y, Rutgeerts PJ.
    Aliment Pharmacol Ther; 2011 Mar 15; 33(5):541-50. PubMed ID: 21223344
    [Abstract] [Full Text] [Related]

  • 14. Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study.
    Sandborn WJ, Schreiber S, Hanauer SB, Colombel JF, Bloomfield R, Lichtenstein GR, PRECiSE 4 Study Investigators.
    Clin Gastroenterol Hepatol; 2010 Aug 15; 8(8):696-702.e1. PubMed ID: 20363366
    [Abstract] [Full Text] [Related]

  • 15. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW, Bickston SJ.
    Cochrane Database Syst Rev; 2008 Jan 23; (1):CD006893. PubMed ID: 18254120
    [Abstract] [Full Text] [Related]

  • 16. Certolizumab pegol: a polyethylene glycolated Fab' fragment of humanized anti-tumor necrosis factor alpha monoclonal antibody for the treatment of Crohn's disease.
    Baker DE.
    Rev Gastroenterol Disord; 2008 Jan 23; 8(4):240-53. PubMed ID: 19107098
    [Abstract] [Full Text] [Related]

  • 17. Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease.
    Colombel JF, Sandborn WJ, Allez M, Dupas JL, Dewit O, D'Haens G, Bouhnik Y, Parker G, Pierre-Louis B, Hébuterne X.
    Clin Gastroenterol Hepatol; 2014 Mar 23; 12(3):423-31.e1. PubMed ID: 24184736
    [Abstract] [Full Text] [Related]

  • 18. Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease.
    Hanauer SB, Panes J, Colombel JF, Bloomfield R, Schreiber S, Sandborn WJ.
    Aliment Pharmacol Ther; 2010 Aug 23; 32(3):384-93. PubMed ID: 20491747
    [Abstract] [Full Text] [Related]

  • 19. Certolizumab pegol: in Crohn's disease.
    Blick SK, Curran MP.
    BioDrugs; 2007 Aug 23; 21(3):195-201; discussion 202-3. PubMed ID: 17516714
    [Abstract] [Full Text] [Related]

  • 20. Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn's disease.
    Feagan BG, Coteur G, Tan S, Keininger DL, Schreiber S.
    Am J Gastroenterol; 2009 Aug 23; 104(8):1976-83. PubMed ID: 19471252
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.